However, after extracting tumor-specific ORRs from some cancer immunotherapy studies, the correlation of CDKN2A ALT frequency with ORRs did not reach statistical significance (r, 0.2; p = 0.28) in TCGA cohort (Figure S3D). The gene discussed is CDKN2A; the disease is neoplasm.